AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22983573 — intervention group
Group type: COMPARATOR
Intervention: Higher hemoglobin F
Number of subjects: 415
Study 22983573 — intervention group
Group type: COMPARATOR
Intervention: Alpha-thalassemia
Number of subjects: 415
Study 22983573 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systemic pulse pressure, lower oxygen saturation, greater values for tricuspid regurgitation velocity, left ventricular diastolic dimension and left ventricular mass
Number of subjects: 415
Study 22983573 — intervention group
Group type: EXPERIMENTAL
Intervention: High hemolytic component
Number of subjects: 415
Study 22983583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, lenalidomide and dexamethasone
Number of subjects: 21
Study 22983877 — intervention group
Group type: EXPERIMENTAL
Intervention: New York University Caregiver Intervention (NYUCI) with case management by a community health worker (CHW)
Number of subjects: 0
Study 22983877 — intervention group
Group type: COMPARATOR
Intervention: Case management by a community health worker (CHW)
Number of subjects: 0
Study 22984218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg daily; 4 weeks on, 2 weeks off)
Number of subjects: 34
Study 22985379 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg riluzole twice daily for 28 doses, starting at a mean of 8.7 ± 2.2 hours postinjury.
Number of subjects: 35
Study 22985381 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 0
Study 22985381 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22987312 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (IM, 400 mg daily)
Number of subjects: 30
Study 22987562 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS) without nerve exposure during intraoperative neuromonitoring (IONM)
Number of subjects: 220
Study 22987562 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of VNS with nerve exposure
Number of subjects: 220
Study 22989031 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP < 1028 ng/L
Number of subjects: 383
Study 22989031 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP
Number of subjects: 383
Study 22989031 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP in patients with concomitant procedure
Number of subjects: 383
Study 22989869 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life scores (measured by RAND36 dimensions: physical functioning and general health)
Number of subjects: 661
Study 22989869 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels
Number of subjects: 661
Study 22989869 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables
Number of subjects: 661
Study 22990093 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic CAH treatment regimen
Number of subjects: 244
Study 22990093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclassic CAH treatment regimen
Number of subjects: 244
Study 22990093 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult CAH patients
Number of subjects: 244
Study 22990093 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic CAH females
Number of subjects: 244
Study 22990093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclassic CAH females
Number of subjects: 244
Study 22990093 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic CAH males
Number of subjects: 244
Study 22990096 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D below 20 ng/ml
Number of subjects: 1193
Study 22990096 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentrations of 24,25-dihydroxyvitamin D
Number of subjects: 1193
Study 22990096 — intervention group
Group type: COMPARATOR
Intervention: 25(OH)D of at least 30 ng/ml
Number of subjects: 1193
Study 22990096 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating vitamin D metabolites
Number of subjects: 1193
Study 22990174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile human acellular dermal matrix
Number of subjects: 65
Study 22990272 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 4047
Study 22990319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.3 or 0.5 mg)
Number of subjects: 19
Study 22990455 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation with lung protective strategies
Number of subjects: 146
Study 22990455 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ventilatory settings at 24 hours post-assessment
Number of subjects: 146
Study 22991217 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent interactive intervention (web-based CME, performance feedback, quality improvement tools)
Number of subjects: 1182
Study 22991217 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1182
Study 22992045 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A H1N1/2009 vaccine
Number of subjects: 95
Study 22992437 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (1010 CFU/day, Ecologic®Performance or OMNi-BiOTiC®POWER)
Number of subjects: 23
Study 22992437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 22992437 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 23
Study 22992566 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitope-based synthetic peptide vaccine candidates containing residues 211-225 of VP1 formulated with Freund's adjuvant (CFA/IFA)
Number of subjects: 0
Study 22992566 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant EV71 subunit vaccine (VP1) expressed in E. coli and formulated with CFA/IFA
Number of subjects: 0
Study 22992566 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA plasmid containing VP1 gene
Number of subjects: 0
Study 22992566 — intervention group
Group type: EXPERIMENTAL
Intervention: VP1 expressed in Salmonella typhimurium
Number of subjects: 0
Study 22992566 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant EV71 virus-like particles (rVLP) produced from baculovirus formulated with CFA/IFA or alum
Number of subjects: 0
Study 22992566 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic peptides or recombinant EV71 subunit vaccines (rVP1 and rVLP) formulated in alum
Number of subjects: 0
Study 22992566 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin-inactivated (FI) EV71 virions formulated in alum
Number of subjects: 0
Study 22993389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone (2.5 mg/kg once daily for 3 days)
Number of subjects: 319
Study 22993389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 319
Study 22993389 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (control group)
Number of subjects: 319
Study 22994896 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled anesthetics
Number of subjects: 54
Study 22994896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthetics
Number of subjects: 54
Study 22994896 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 22995059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake as per American Heart Association and National Heart, Lung, and Blood Institute nutrition parameters
Number of subjects: 361
Study 22995059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary recommendations for urban African Americans
Number of subjects: 361
Study 22995650 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) in the refractory group
Number of subjects: 45
Study 22995650 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) in the naive group
Number of subjects: 45
Study 22995726 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 422
Study 22995726 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 422
Study 22995726 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (postoperative within 5 days after withdrawal)
Number of subjects: 422
Study 22995875 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (IS)
Number of subjects: 1645
Study 22995875 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (CS)
Number of subjects: 1645
Study 22995885 — intervention group
Group type: EXPERIMENTAL
Intervention: High frailty score group
Number of subjects: 159
Study 22995885 — intervention group
Group type: COMPARATOR
Intervention: Lower frailty score group
Number of subjects: 159
Study 22996144 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) for 72 hours before and at 3, 6, 9, 12, 24, and 36 months after transplantation
Number of subjects: 23
Study 22996144 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 23
Study 22996616 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 186
Study 22996616 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine IR
Number of subjects: 186
Study 22996616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 186
Study 22997219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST)
Number of subjects: 330
Study 22997219 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN)-γ release assays (IGRAs)
Number of subjects: 330
Study 22997219 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-γ-induced protein (IP)-10
Number of subjects: 330
Study 22997219 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive use of TST, IGRA, and IP-10
Number of subjects: 330
Study 22997219 — intervention group
Group type: EXPERIMENTAL
Intervention: Using three tests (TST, IGRA, IP-10)
Number of subjects: 330
Study 22997219 — intervention group
Group type: EXPERIMENTAL
Intervention: Single test use
Number of subjects: 330
Study 22997219 — intervention group
Group type: COMPARATOR
Intervention: Control group (156 children)
Number of subjects: 330
Study 22998112 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Number of subjects: 130
Study 22998112 — intervention group
Group type: COMPARATOR
Intervention: RAPIDLab® 1265 blood gas analyser (BGA)
Number of subjects: 130
Study 22998355 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting coronary stent system (EECSS)
Number of subjects: 5054
Study 22998907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical oportuzumab monatox (30 mg) - cohort 1 (6 weekly instillations)
Number of subjects: 46
Study 22998907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical oportuzumab monatox (30 mg) - cohort 2 (12 weekly instillations)
Number of subjects: 46
Study 22998907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical oportuzumab monatox (30 mg)
Number of subjects: 46
Study 22999213 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - calcic nadroparin, administered daily for one month.
Number of subjects: 0
Study 22999213 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - single dose of calcium nadroparin, studied for 12 hours.
Number of subjects: 0
Study 22999294 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 4 mg/kg via monthly intramuscular injections for 12 months
Number of subjects: 30
Study 22999729 — intervention group
Group type: EXPERIMENTAL
Intervention: Central to peripheral pulse pressure amplification (PPA)
Number of subjects: 1126
Study 22999729 — intervention group
Group type: COMPARATOR
Intervention: High blood pressure (BP)
Number of subjects: 1126
Study 23000321 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23000649 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical thalidomide gel
Number of subjects: 0
Study 23001085 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus monotherapy with donor bone marrow cell infusion
Number of subjects: 5
Study 23001257 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Sjögren's syndrome (SS)
Number of subjects: 327
Study 23001257 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ANA
Number of subjects: 327
Study 23001257 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive RF
Number of subjects: 327
Study 23001391 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia Nervosa (BN)
Number of subjects: 76
Study 23001391 — intervention group
Group type: EXPERIMENTAL
Intervention: BN-type eating disorder not otherwise specified
Number of subjects: 76
Study 23001391 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 76
Study 23002195 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac defibrillator (ICD) therapy
Number of subjects: 235
Study 23006321 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg bid
Number of subjects: 69
Study 23006321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundoplication
Number of subjects: 69
Study 23006802 — intervention group
Group type: EXPERIMENTAL
Intervention: E-MOSAIC software installed in handheld computer generating a longitudinal monitoring sheet (LoMoS) provided to oncologists
Number of subjects: 80
Study 23006802 — intervention group
Group type: COMPARATOR
Intervention: Standard care without LoMoS
Number of subjects: 80
Study 23006802 — intervention group
Group type: EXPERIMENTAL
Intervention: E-MOSAIC software
Number of subjects: 80
Study 23007406 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele at rs7142143 in the PYGL gene
Number of subjects: 2535
Study 23007406 — intervention group
Group type: EXPERIMENTAL
Intervention: 134 SNPs associated with ALL relapse
Number of subjects: 2535
Study 23007406 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs including variants in PDE4B and ABCB1
Number of subjects: 2535
Study 23007746 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 4 g daily
Number of subjects: 30
Study 23008465 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 500 U/kg
Number of subjects: 24
Study 23008465 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 1000 U/kg
Number of subjects: 24
Study 23008465 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 2500 U/kg
Number of subjects: 24
Study 23008465 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 24
Study 23009127 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive iodine remnant ablation
Number of subjects: 0
Study 23009552 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch, mean maintenance dose 3.1 ± 1.1 mg/24 h
Number of subjects: 295
Study 23009552 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 295
Study 23009652 — intervention group
Group type: EXPERIMENTAL
Intervention: PHMB-based gynecological solution (Monogin®, Lo.Li. Pharma, Rome - Italy) for six months
Number of subjects: 100
Study 23009652 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 100
Study 23010228 — intervention group
Group type: EXPERIMENTAL
Intervention: Puff City, a web-based, tailored asthma management intervention
Number of subjects: 0
Study 23010228 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23010851 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral dose of (14)C-dovitinib
Number of subjects: 13
Study 23010851 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg daily nonlabeled dovitinib (continuous-dosing extension phase)
Number of subjects: 13
Study 23010851 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to dovitinib
Number of subjects: 13
Study 23011914 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint physical activity in residential locations (35%)
Number of subjects: 291
Study 23011914 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint physical activity in commercial venues (24%)
Number of subjects: 291
Study 23011914 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint physical activity in open spaces/parks (20%)
Number of subjects: 291
Study 23011914 — intervention group
Group type: COMPARATOR
Intervention: Joint physical activity comparison between obese and under/normal weight children and parents
Number of subjects: 291
Study 23012326 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hIL-7 (CYT107) administered weekly for 3 weeks
Number of subjects: 12
Study 23012326 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 23013426 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTS Burdens scale (12-item)
Number of subjects: 1336
Study 23013426 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTS Benefits scale (3-item)
Number of subjects: 1336
Study 23014345 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IFN-γ pretreatment
Number of subjects: 12
Study 23014524 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC enumeration in 7.5 mL of blood
Number of subjects: 836
Study 23014524 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC concentration
Number of subjects: 836
Study 23014524 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry for CTC detection
Number of subjects: 836
Study 23014524 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC frequency
Number of subjects: 836
Study 23016889 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 700
Study 23016889 — intervention group
Group type: COMPARATOR
Intervention: Untreated coeliac patients
Number of subjects: 700
Study 23018280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 or 15 mg/kg) every 3 weeks plus chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression.
Number of subjects: 215
Study 23018312 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23018547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole monotherapy (10-30 mg/day)
Number of subjects: 361
Study 23018646 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher RBC α-linolenic acid (T3)
Number of subjects: 400
Study 23018646 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher RBC eicosapentaenoic acid (T3)
Number of subjects: 400
Study 23018646 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total n-3 PUFAs (T3)
Number of subjects: 400
Study 23018646 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher RBC n-6/n-3 ratio (T3)
Number of subjects: 400
Study 23018646 — intervention group
Group type: COMPARATOR
Intervention: RBC PUFAs
Number of subjects: 400
Study 23018816 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood IgG antibody titer test against Porphyromonas gingivalis
Number of subjects: 1387
Study 23018816 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 1387
Study 23018816 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis
Number of subjects: 1387
Study 23018816 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplied cut-off values
Number of subjects: 1387
Study 23018901 — intervention group
Group type: EXPERIMENTAL
Intervention: pCLE in HP-AMR-IP patients
Number of subjects: 36
Study 23018901 — intervention group
Group type: COMPARATOR
Intervention: pCLE in LP-AMR-IP patients
Number of subjects: 36
Study 23018901 — intervention group
Group type: COMPARATOR
Intervention: pCLE in ILD patients not receiving amiodarone
Number of subjects: 36
Study 23018901 — intervention group
Group type: COMPARATOR
Intervention: pCLE in amiodarone-treated patients without ILD
Number of subjects: 36
Study 23018901 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic accuracy of pCLE for AMR-IP
Number of subjects: 36
Study 23019248 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 0
Study 23020584 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFIRI
Number of subjects: 154
Study 23020932 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced diabetic retinopathy (DR)
Number of subjects: 15773
Study 23020932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin (Hb) A(1c), diabetes duration and treatment, particularly with insulin, hypertension, previous cardiovascular disease (CVD), albuminuria
Number of subjects: 15773
Study 23020932 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 15773
Study 23020932 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, age at diabetes diagnosis, smoking, estimated glomerular filtration rate
Number of subjects: 15773
Study 23021166 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness gastroplication
Number of subjects: 36
Study 23021483 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggression
Number of subjects: 115
Study 23021483 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 115
Study 23021483 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate mania
Number of subjects: 115
Study 23021515 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone (TT) levels
Number of subjects: 68
Study 23021515 — intervention group
Group type: EXPERIMENTAL
Intervention: Free testosterone (FT) levels
Number of subjects: 68
Study 23021515 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) levels
Number of subjects: 68
Study 23021515 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypogonadism prevalence
Number of subjects: 68
Study 23021515 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 68
Study 23022045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib combined with docetaxel and trastuzumab
Number of subjects: 26
Study 23022496 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoplastic polyp removal
Number of subjects: 1427
Study 23022496 — intervention group
Group type: EXPERIMENTAL
Intervention: Large neoplastic polyps (10-20 mm)
Number of subjects: 1427
Study 23022496 — intervention group
Group type: EXPERIMENTAL
Intervention: Small neoplastic polyps (5-9 mm)
Number of subjects: 1427
Study 23022496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sessile serrated adenomas/polyps
Number of subjects: 1427
Study 23022496 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional adenomas
Number of subjects: 1427